6533b855fe1ef96bd12b0711

RESEARCH PRODUCT

Итоговое резюме KDIGO 2018 по гепатиту С для рекомендаций по ХБП: достижения в оценке и менеджменте

Mengyang DiMarina BerenguerMichel JadoulWahid DossJacques IzopetFabrizio FabriziStanislas PolAmy EarleyVivekanand JhaVivekanand JhaEthan M BalkCraig E. GordonPriti R. PatelPaul J. MartinChing-lung LaiNassim KamarNassim KamarBertram L. KasiskeJosé M. MoralesMarcelo Silva

subject

medicine.medical_specialtyDialysis TherapyExecutive summarybusiness.industryHepatitis C virusLiver fibrosisvirus diseasesHepatitis CGuidelinemedicine.diseasemedicine.disease_causemedicineIn patientIntensive care medicinebusinessKidney disease

description

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.

yearjournalcountryeditionlanguage
2021-09-08KIDNEYS
https://doi.org/10.22141/2307-1257.7.4.2018.148514